III-27 Elisa Borella
Vaborem pharmacokinetics and dose rationale in children
|
III-28 Elisa Borella
Oritavancin pharmacokinetics and dose rationale in children
|
III-29 Salvatore D'Agate
Model-based evaluation of beta-lactams in neonatal and paediatric sepsis
|
III-30 Eva Degraeuwe
Population pharmacokinetic modeling of lisinopril at steady-state in hypertensive pediatric patients with mild to moderate renal impairment
|
III-31 Esther Encinas
Simulation of systemic exposure after multiple ocular administration of bilastine ophthalmic solution for safety assessment in children
|
III-32 Aline Engbers
Lack of pharmacokinetic interaction between doxapram and caffeine for the treatment of preterm infants with apnea
|
III-33 Alan Faraj
Phase-3 dose selection of marzeptacog alfa (activated) in children enabled by model-informed drug development techniques
|
III-34 Kinga Fiebig
Prospective evaluation of a novel model-based dosing guideline for gentamicin in preterm and term neonates
|
III-35 Anthony Gebhart
A semi-physiologically based pharmacokinetics approach to predict hepatic and gut wall intrinsic clearances of midazolam in pediatric patients: preliminary results filling the gap between preterm neonates and infants above 1 year
|
III-36 Iztok Grabnar
Pharmacokinetic-pharmacodynamic model of fentanyl sedation in children with severe acute bronchiolitis
|
III-37 Ana-Marija Grisic
Population pharmacokinetic model of avelumab in a pediatrics population
|
III-38 Soumya Perinparajah
A Novel Mechanistic Mathematical Model for CD19+ B Cell Reconstitution after Paediatric Haematopoietic Stem Cell Transplantation
|
III-39 Maša Roganović
Population pharmacokinetic modelling of cyclosporine in paediatric kidney transplant patients using routine TDM data
|
III-40 Rajendra Singh
Determination of the individual pharmacokinetic exposure parameter uncertainty to support of pediatric exposure-response trial design
|
III-41 Rajendra Singh
Population pharmacokinetic analysis of deutetrabenazine (AUSTEDO) in children and adolescents with Tourette Syndrome
|
III-42 Erik Sjögren
Lumenfantrine Exposure in Malnourished Children: PBPK modeling applied for Predictions and Dose Adjustments
|
III-43 Tomás Sou
Caplacizumab Model-Based Dosing Recommendations In Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura
|
III-44 Marinda van de Kreeke
Quantifying requirements for additional sedatives in critically-ill children using a repeated time to event analysis
|
III-45 Louvina van der Laan
Pharmacokinetics of para-aminosalicylic acid in children treated for multidrug-resistant tuberculosis.
|
III-46 Yunjiao Wu
Pre- and postnatal maturation are important for fentanyl exposure in preterm and term newborns: a pooled population pharmacokinetic study
|
